ORG 25935

Drug Profile

ORG 25935

Alternative Names: Glycine uptake inhibitor; ORG25935; SCH 900435

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Organon
  • Developer Merck & Co; Organon
  • Class Tetrahydronaphthalenes
  • Mechanism of Action Glycine transporter 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alcoholism; Panic disorder; Schizophrenia

Most Recent Events

  • 03 Mar 2010 Discontinued - Phase-II for Panic disorder in USA (PO)
  • 24 Feb 2010 Schering-Plough completes enrolment in a phase II trial for panic disorders in USA
  • 15 Jan 2008 Pharmacodynamics data from a preclinical study in rats and monkeys presented at the 20th Annual Congress of the European College of Neuropsychopharmacology (ECNP-2007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top